NR1H4 and metabolic dysfunction-associated steatohepatitis: Third, the FXR agonist obeticholic acid has been demonstrated to have promising clinical results in the treatment of liver disorders such as primary biliary cirrhosis, primary sclerosing cholangitis, and nonalcoholic steatohepatitis [40].